Intelligence / Healthtech / New Clinical Trials / Kyorin Pharmaceutical Co.,Ltd
Kyorin Pharmaceutical Co.,Ltd
5 Nov 2026: Trial registered · A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 5 Nov 2026
- Title
- A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants
- Conditions
- Healthy Participants
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Canada
- Country
- Canada
- Reference
- NCT07919314
- Location
- Canada
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Kyorin Pharmaceutical Co.,Ltd
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Canada
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.